CagriSema
InvestigationalAlso known as: Cagrilintide-Semaglutide, NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
Research Statistics
Phase 3 cagrilintide+semaglutide combination with global trials and dual-mechanism support.
Research Dossier
Overview
What is CagriSema and what does the research say?
Mechanism of Action
CagriSema combines two distinct appetite-suppressing peptide hormones into a single weekly injection, targeting complementary pathways in the brain.
How It Works (Simplified)
GLP-1 (semaglutide) and amylin (cagrilintide) activate separate “stop eating” pathways in the brain, creating a stronger combined appetite suppression effect.
Semaglutide targets the hypothalamus (hunger center) while cagrilintide additionally affects the hindbrain and septum (satiety and reward areas).
Clinical trials show the combination produces MORE weight loss than adding the two drugs together would predict, indicating true pharmacological synergy.
For people with prediabetes or diabetes, the combination improves blood sugar control more effectively than either component alone.
Scientific Pathways
GLP-1 Pathway (Semaglutide)
Semaglutide → GLP-1R activation → Hypothalamus
↓
├── POMC/CART activation → satiety increase
├── NPY/AgRP inhibition → hunger decrease
└── Glucose-dependent insulin secretionAmylin Pathway (Cagrilintide)
Cagrilintide → AMY1R/AMY2R/AMY3R/CTR activation → Hindbrain
↓
├── Area postrema signaling → meal termination
├── Nucleus tractus solitarius → satiety
└── Reduced postprandial glucagonKey Research: Rubino DM et al. demonstrated in REDEFINE-1 that CagriSema produces weight loss exceeding the sum of individual components. PMID:40544432
Important Limitations
- FDA approval pending (NDA submitted December 2025)
- Long-term safety data beyond 68 weeks not yet available
- No head-to-head comparison with tirzepatide
- Cardiovascular outcomes trial (REDEFINE-3) still ongoing
- GI side effects occur in approximately 80% of patients (mostly mild-moderate, transient)
- Weight maintenance after discontinuation unknown
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Dose titration phase. GI side effects (nausea, vomiting, diarrhea) most common during initiation. Appetite suppression typically begins within first 1-2 weeks.
Continued dose escalation to maintenance dose. Weight loss acceleration observed. GI side effects typically diminish as tolerance develops.
Maintenance phase with ongoing weight loss. REDEFINE trials showed approximately 15-18% weight loss achieved by this timepoint.
Continued weight loss with plateau approaching. Final weight loss of 22.7% achieved at 68 weeks. Cardiometabolic improvements sustained.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate CagriSema product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining CagriSema with other peptides. Based on published research and mechanistic considerations.
BPC-157
CautionBoth affect GI function. BPC-157 is gastroprotective while semaglutide component slows gastric emptying. Monitor GI symptoms if combined.
Semaglutide
AvoidCagriSema already contains semaglutide. Combining with additional semaglutide would result in overdose. Do not use concurrently.
Tirzepatide
AvoidBoth are GLP-1 receptor agonists for weight management. Concurrent use would cause overlapping mechanisms and increased adverse effects.
Liraglutide
AvoidLiraglutide is a GLP-1 agonist. Combining with CagriSema would duplicate GLP-1 pathway activation and increase GI adverse effects.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare CagriSema
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium, NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111, Oral Amycretin, Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. Phase 1b results showed 18.8% placebo-adjusted weight loss at 24 weeks, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
Liraglutide
Victoza, Saxenda, NN2211
The first long-acting GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Pioneered the therapeutic class with proven cardiovascular benefits in the landmark LEADER trial.
MariTide
AMG 133, maridebart cafraglutide
A bispecific peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism. Unique mechanism opposite to tirzepatide. Phase 2 showed ~20% weight loss at 52 weeks with once-monthly dosing. MARITIME Phase 3 program initiated.